Cryogenic Solutions --CYGS-- Becomes CytoGenix --CYGX--.

Business Editors/Health &Medical Writers

HOUSTON--(BUSINESS WIRE)--Jan. 31, 2000

Cryogenic Solutions Inc. (CYGS) has changed its name. The shareholders present at the annual shareholders meeting on Dec. 16, 1999 voted unanimously for the new name, CytoGenix Inc. (OTCBB:CYGXE). The name change is designed to more accurately reflect the company's fundamental research objectives and its focus on cellular biology, molecular biotechnology, pharmacogenomics and genetics.

The name change to CytoGenix(TM) requires a new OTC BB symbol and CYGX was designated. The symbol currently has an &uot;E&uot; appended pending the resolution of regulatory reporting issues. Currently information and quotes can be found under CYGXE.

The new web address will be http://www.cytogenix.com. The website is being expanded and redesigned to be more easily navigated with improved graphics and simplified language describing the CytoGenix(TM) technology. It will include a &uot;guest book&uot; registration where interested shareholders can add their email address for instant notification of items of interest.

The CytoGenix(TM) name was introduced to over 600 leading compounding pharmacists at the January Seminar conducted by Professional Compounding Centers of America, PCCA, the partner of CYGX in their joint enterprise, PharmaGenix, LLC which combines traditional pharmaceutical compounding with the emerging genetic technologies.

The role of PharmaGenix(TM) is to support compounding pharmacists, patients, and physicians and assist in the utilization of the new technologies that are emerging in the evolution of customized healthcare products.

Jonathan Elliston, Ph.D., of CytoGenix(TM) offered a lunch time presentation detailing the role of TroVec(TM), the company's proprietary ssDNA intracellular expression vector that enables the many promising &uot;antisense&uot; molecules now being identified and patented by leading biotechs around the world.

Dr. Elliston explained the difference between gene therapy and antisense. &uot;Gene therapy involves actually modifying the genetic code within the chromosomes of selected cells. This can have varied and far reaching results, not all of which can be anticipated. Antisense however, simply intercepts the messenger RNA that the DNA in the chromosomes uses to send instructions. This prevents the production of the harmful proteins that make us sick. Gene therapy is analogous to rewriting the operating system of your computer while antisense is more like deleting a file.&uot;

An integral part of the PharmaGenix(TM) services will be development and presentation of educational programs, materials, and web offerings to introduce the concepts of pharmacogenomics to students, pharmacists and physicians. The programs will include presentations at professional meetings and seminars; articles in the PCCA journal, &uot;The Apothegram&uot;; and other printed material, videos, CD-ROMs, and software. In addition, a comprehensive continuing education presence will be maintained on the web at http://www.pharmagenix.com, currently under construction.

Additional information about CytoGenix(TM) and its technology can be found on the website at http://www.cytogenix.com.